Rotavirus vaccine - National Resilience
Latest Information Update: 25 Oct 2021
At a glance
- Originator Nanotherapeutics
- Developer National Resilience
- Class Rotavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rotavirus infections
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Rotavirus-infections(Prevention) in USA
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 25 Jan 2017 Preclinical trials in Rotavirus infections (Prevention) in USA before January 2017 (Nanotherapeutics pipeline, January 2017)